Related Experiment Video
Updated: Jun 8, 2025
04:23
The Creation of a Rat Model for Osteosarcopenia via Ovariectomy
Published on: February 21, 2025
241
Drug risks associated with sarcopenia: a real-world and GWAS study
1The Affiliated Yixing Hospital of Jiangsu University, Yixing, Jiangsu, 214200, China.
BMC Pharmacology & Toxicology
|November 8, 2024
Summary
Metformin, aspirin, and acetaminophen are linked to drug-induced sarcopenia. This study analyzed adverse event reports and genetic data to identify risks and guide safe medication use for preventing muscle loss.
Area of Science:
- Pharmacovigilance
- Genetics
- Gerontology
Background:
- Drug-induced sarcopenia is under-recognized, despite the growing importance of medication safety monitoring.
- Effective pharmacovigilance is crucial for assessing the benefit-risk profiles of drugs.
Purpose of the Study:
- To investigate the association between drug use and sarcopenia using FDA Adverse Event Reporting System (FAERS) data.
- To evaluate genetic factors contributing to drug-induced sarcopenia via summary-data-based Mendelian randomization (SMR).
Main Methods:
- Analyzed FAERS data for adverse drug reactions, focusing on sarcopenia and potential sarcopenia.
- Calculated Proportional Reporting Ratio (PRR) to assess drug-specific risks.
- Employed SMR with Genome-wide association study (GWAS) data to link drug targets to sarcopenia outcomes (hand grip strength, appendicular lean mass).
Main Results:
- Identified 55 drugs with potential sarcopenia risk and 3 with confirmed risk: metformin, aspirin, and acetaminophen.
- Top potential risks included levofloxacin, pregabalin, atorvastatin, duloxetine, and venlafaxine.
- SMR indicated a negative correlation between ETFDH gene expression and muscle strength/mass.
Conclusions:
- Metformin, aspirin, and acetaminophen are specifically associated with drug-induced sarcopenia.
- Real-world data analysis provides guidance for safe medication use to prevent sarcopenia.
- Highlights the need for increased attention to drug-induced sarcopenia in clinical practice and pharmacovigilance.
Related Concept Videos
01:11Genome-wide Association Studies-GWAS
12.5K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
12.5K
01:29Bone Disorders
3.4K
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
3.4K